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ABSTRACT 
BACKGROUND: The functions of many proteins are tightly regulated with a complex array 
of cellular functions including ubiquitination. In cancer cells, aberrant ubiquitination may 
promote the activity of oncogenic pathways with subsequent tumour progression. Kelch-like 
family member 7 (KLHL7) is involved in the regulation of ubiquitination and may play a role 
in breast cancer (BC). Present study aims to evaluate the biological and clinical usefulness of 
KLHL7 in BC utilising large well-characterised cohorts with long follow up term.  
METHODS: The relationships between KLHL7 gene copy number alteration (CNA) and 
mRNA expression and clinicopathological variables and clinical outcomes were evaluated in 
1980 patients from the METABRIC BC cohort. Prognostic significance of KLHL7 mRNA 
was validated using the Breast Cancer Gene-Expression Miner v4.0 datasets (n = 5206). 
KLHL7 protein expression was assessed using immunohistochemistry in a large annotated 
series of early-stage BC (n=917) with long-term follow-up.  
RESULTS: KLHL7 CNA was significantly correlated with its mRNA expression. KLHL7 
mRNA expression was higher in luminal B and basal-like molecular subtypes and in higher 
grade tumours. Increased KLHL7 protein expression was significantly correlated with 
features of aggressive phenotype including lymphovascular invasion, high histological grade, 
hormonal receptor negativity, high PIK3CA and p53 expression. Outcome analysis showed 
that high KLHL7 expression is an independent predictor of shorter survival (p = 0.0011).  
CONCLUSIONS: KLHL7 appears to play an important role in BC progression. High 
KLHL7 protein expression identified a subgroup of BC with aggressive behaviour and 
provided independent prognostic information. 
 
 
 
 INTRODUCTION 
Advances in early detection, diagnosis and refinement of prognostic and therapy prediction 
have led to improvement of the outcome of invasive breast cancer however; approximately 
20% of early-stage breast cancer patients still experience recurrence and metastasis [1, 2]. 
Identification of genes significantly associated with tumour progression providing potential 
therapeutic values remains as one of the main goals of breast cancer research. The functions 
of many proteins are controlled by ubiquitination [3, 4], and in cancer cells, abnormal 
ubiquitination may promote the activity of oncogenic pathways [5, 6], enhance tumour 
proliferation, migration, invasion, angiogenesis, epithelial–mesenchymal transition and 
metastasis [7, 8]. Kelch-like family member 7 (KLHL7), which is a member of the Kelch 
protein family associated with the development of retinitis pigmentosa [9, 10], forms a 
ubiquitin ligase complex by binding to the BTB and BACK domains of Cullin3 (CUL3) [10, 
11]. This binding facilitates proteasome degradation of target proteins by enhancing E2 or E3 
ligase activity and polyubiquitination [10-12]. KLHL7 is considered to be crucial for 
regulating the protein homeostasis and its aberrant expression has also been associated with 
cancer cell proliferation [13-16]. However; the role of KLHL7 in breast cancer has not been 
established.  
In this study we investigated the biological and clinical significance of KLHL7 in breast 
cancer at the genetic transcriptomic and protein levels. KLHL7 copy number alterations 
(CNA) and mRNA expression as well as KLHL7 protein expression assessed using 
immunohistochemistry was correlated with clinicopathological features and outcome using 
large well-characterised cohorts of early-stage breast cancer. 
 
MATERIALS AND METHODS  
KLHL7 gene copy number and mRNA expression 
The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset, 
containing 1980 invasive breast cancers [17, 18], was explored for genomic/transcriptomic 
profiling of KLHL7. In the METABRIC study, DNA and RNA extracted from primary 
tumour samples were hybridised using Affymetrix SNP 6.0 arrays (Affymetrix, Inc., Santa 
Clara, USA) and Illumina Human HT-12 v3 platforms (Illumina, Inc., San Diego, USA) . All 
patients were treated uniformly. Oestrogen receptor (ER)-positive breast cancer patients with 
lymph node-negative were not offered adjuvant chemotherapy. ER-negative or lymph node-
positive patients were treated with adjuvant chemotherapy. No human epithelial growth 
factor 2 (HER2)-positive patients received therapy with trastuzumab. None of the patients 
included in the study received neoadjuvant treatment. 
The prognostic value of KLHL7 mRNA expression was further evaluated using the Breast 
Cancer Gene-Expression Miner v4.0 (bc-GenExMiner v4.0) database which includes 5861 
breast cancer patients [19].  
 
KLHL7 protein expression 
KLHL7 protein expression was assessed in large (n=917) cohort of early-stage breast cancer 
from surgically treated patients presented to Nottingham City Hospital, UK between 1989 
and 1998. Tissue microarray (TMA) sections were stained using specific anti-KLHL7 
antibody (see below). No patients underwent neoadjuvant treatment before initial breast 
surgery. In this study, 917 cases were informative for the biomarker expression. 
Lymphovascular invasion (LVI) was evaluated by haematoxylin and eosin staining and 
immunostaining for CD34 or D2-40 as previously described [20]. Patient characteristics were 
shown in Supplementary Table 1. Data on ER, progesterone receptor (PR), HER2, Ki67, 
phosphatidylinositol 3-kinase (PIK3CA), p53 and phospho-Akt1 (pAkt) were available and 
were assessed as previously described [21-26]. ER-positive/HER2-negative breast cancer 
patients with PR-positive and low Ki67 staining (labelling index of ≤ 10%) were classified as 
luminal A-like type; other ER-positive patients were classified as luminal B-like type. 
Patients who were ER-positive and/or PR-positive and HER2-positive were defines as 
luminal-HER2 [27].  
The specificity of KLHL7 antibody (HPA029491, Merck, Germany) was confirmed using 
Western blotting and MCF-7 and Jurkat cell lines (The American Type Culture Collection; 
Rockville, MD, USA).  This showed primary antibody specificity; with a single band 
observed at approximately 70 kDa in both cell lines (Supplementary Figure 2).  
KLHL7 protein expression was characterized immunohistochemically (IHC) in 15 full-face 
breast cancer tissue sections prior to TMA application. IHC assays were performed using 
Novolink Max Polymer Detection System (RE7280-k, Leica, Newcastle, UK). The anti-
KLHL7 primary antibody was diluted 1:100 in Bond Primary Antibody Diluent (Leica, 
Germany). A polyclonal rabbit anti-human beta-2-microglobulin antibody (diluted 1:2000; 
Dako, Glostrup, Denmark) was used as a positive staining control. Diaminobenzidine 
tetrahydrochloride (Novolink DAB substrate buffer plus) was used as the chromogen; 
sections were counterstained with Meyer’s haematoxylin for 6 min.  
Immunostained TMA sections were digitally scanned into high-resolution digital images 
(NanoZoomer, Hamamatsu Photonics, Tokyo, Japan) and viewed using Aperio Image Scope 
(Aperio Technologies, Milton Keynes, UK). KLHL7 expression was scored as none, weak, 
moderate or strong depending on the intensity of cytoplasmic staining (Figure 1). 
Cytoplasmic expression was assessed, and H-scores were calculated using the proportion of 
stained cells (0%–100%) and intensity scores (0, negative; 1, weak; 2, moderate; 3, strong) as 
previously described [28, 29].  
 
Statistical analysis 
Statistical analysis was performed with SPSS v22.0 (IBM Corp., Armonk, NY, USA). 
The association of KLHL7 mRNA expression and CNA was assessed using the Kruskal–
Wallis test. The significance of differences in CNA and mRNA expression in tumours 
stratified by PAM50 subtype, size, lymph node metastasis grade and histological grade was 
determined using the Chi-squared and Fisher’s exact tests. For analysis, tissue samples were 
assigned to high- and low-expression groups using the median mRNA expression level as the 
cut-off. For KLHL7 expression, the cut-off was an H-score of 90 determined by X-Tile 
plotting (X-Tile Bioinformatics Software, Yale University, version 3.6.1), with the samples 
stratified to high and low groups based on patient outcome. For the association between 
KLHL7 and prognosis, Kaplan–Meier survival curves of 10-year breast cancer specific 
survival (BCSS) were plotted, and significance was determined by the log-rank test. As the 
patients in the Nottingham primary series were followed-up for at least 10 years, BCSS was 
defined as the interval from surgery to death from breast cancer. In univariate and 
multivariate analyses of clinicopathological factors and KLHL7 expression and prognosis, 
95% confidence interval (CI) values were determined using the Cox proportional hazards 
regression model.  
RESULTS 
KLHL7 Copy number aberration and mRNA expression 
A total of 150 of 1980 patients (7.6%) had a copy number gain whereas 23 (1.7%) had a loss 
of KLHL7. KLHL7 mRNA expression was significantly higher in samples with CNA gain 
than in CNA-neutrals (p < 0.0001). The expression was significantly lower in tumours with 
CNA loss than in CNA-neutral tissues (p = 0.042). KLHL7 CNAs were significantly 
correlated with molecular subtype (p < 0.0001); KLHL7 gain was higher in HER2-enriched 
tumours, whereas KLHL7 loss was more frequent in basal-like tumours than in other subtypes 
(Table 1). High KLHL7 mRNA expression was significantly related with high histological 
grade (p = 0.010) and molecular subtypes (p < 0.0001); high expression in HER2-enriched 
tumours and low in basal-like tumours (Table 1).  
Although the association between KLHL7 CNA and mRNA expression and outcome was not 
significant in the METABRIC series (Supplementary Figure 3), it was significant in the 
larger series of the Breast Cancer Gene-Expression Miner v4.0 with an association between 
high KLHL7 mRNA expression and shorter survival (hazard ratio (HR) =1.3; p<0.0001; 
Figure 2-a).  
 
KLHL7 protein expression 
In full-face sections, the expression of KLHL7 protein was variable in the different 
components of tissues with increased expression in invasive tumours cells than DCIS and 
normal parenchymal cells (Figure 3). Fibroblasts and lymphocytes in the mammary stroma 
adjacent to the cancer cells showed negative to weak staining. In normal glandular 
epithelium, the reactivity of IHC was absent to weak and the reactivity of myoepithelial cells 
tended to be higher than those of glandular cells. The reactivity of myoepithelial cells 
surrounding DCIS was higher compared to the intraductal malignant epithelial cells. KLHL7 
positivity was recognised in the cytoplasm of invasive cancer cells and the reactivity in both 
was substantially stronger compared to normal mammary gland cells if positive. Focal weak 
to moderate nuclear immunoreactivity was seen in the tumour cells simultaneously with 
cytoplasmic staining. 
 
Clinicopathological and prognostic significance of KLHL7 protein expression 
Of the 917 patients, 407 (44.4%) had tumours with low KLHL7 expression whereas 510 
(55.6%) had tumours with high expression (H-score > 90). KLHL7 expression was positively 
correlated with histological grade (p = 0.0002) and LVI status (p = 0.030) but inversely 
correlated with ER status (p = 0.015, Table 2). High KLHL7 expression was significantly 
related with molecular subtypes (p = 0.026), especially HER2-positive and triple-negative 
breast cancer (TNBC) classes (Table 2). High KLHL7 expression was significantly 
associated with high expression of PIK3CA (p = 0.044) and p53 (p = 0.002), but not pAkt 
expression (Table 2). 
The 10-year BCSS of the subgroup with KLHL7 high expression was significantly shorter 
than that of the subgroup with KLHL7 low expression (HR = 9.1; p = 0.0025; Figure 2-b). 
Univariate analysis identified high KLHL7 expression (HR = 1.5; p = 0.003), ER negativity 
(HR = 1.9; p < 0.0001), PR negativity (HR = 2.3; p < 0.0001), HER2 positivity (HR = 2.3; p 
< 0.0001), large tumour size (HR = 2.3; p < 0.0001), positive nodal status (HR = 2.6; p < 
0.0001), histological grade 3 (HR = 3.3; p < 0.0001), positive LVI (HR = 2.4; p < 0.0001) 
and high p53 expression (HR = 1.9; p < 0.0001) as poor prognostic factors.  
In multivariate analysis including other prognostic variables, KLHL7 expression remained 
independently associated with poor prognosis (HR = 1.3; p = 0.042; Table 3). 
 
DISCUSSION 
KLHL7 forms a ubiquitin ligase complex and regulates ubiquitination [9, 10]; however, 
there is a critical lack of knowledge of the targets of KLHL7 ubiquitination in breast cancer. 
In the present study, we revealed the significant association of KLHL7 expression with p53 
suggesting that aberrant KLHL7 ubiquitination may be responsible for decreased p53 
function. Several E3 ubiquitin ligases are thought to regulate p53 expression in cancer [30, 
31]. The function of p53 have been known to play important role in genomic stability, cell 
cycling and apoptosis [32,33] with p53 suppressing cell proliferation in breast cancer cells 
[34-36]. The function of p53 is also associated with activation of PI3K/Akt signalling 
pathway [37]. In a previous study, high p53 protein expression significantly correlated with 
high PIK3CA protein expression [24]. Activation of PI3K pathway is regulated by growth 
factors through transmembrane receptor [38]. The breast cancer with PIK3CA mutations 
have frequently aberrant activation of PI3K pathway [38]. Approximately 20-25% of breast 
cancer have PIK3CA mutations [39]. Previous studies suggest that breast cancer become 
resistant to treatment by activating the PI3K/Akt signalling pathway [40, 41]. Recent clinical 
trials indicated that PI3K inhibitor [42] and mTOR inhibitor [43], which inhibit the activity of 
PI3K/Akt signalling pathway, were useful for the treatment of metastatic breast cancer 
patients. The current study indicates the positive relationship between KLHL7 and PIK3CA 
expression. Further functional studies are necessary to explore the association of aberrant 
ubiquitination caused by KLHL7 overexpression with PI3K/Akt signalling pathway activity 
in breast cancer.       
LVI is involved in breast cancer metastasis and is a recognised prognostic factor [44-47]. In 
this study, KLHL7 expression was significantly associated with positive LVI status, negative 
ER status and TNBC. KLHL7 is located at 7p15, which shows frequent copy number 
alteration in basal-like subtype [48]. A recent genetic analysis of TNBC cases identified 
mesenchymal and mesenchymal stem-like subtypes to be high expressers of epithelial 
mesenchymal transition (EMT) - and cancer stem cell-related genes [49, 50]. Ubiquitination 
is thought to influence cancer stem cell-like properties in breast cancer, and E3 ligases may 
be active in cancer stem cell growth [8].  A recent study reported that the C-terminus of heat 
shock cognate 71 kDa (HSC70) interacting protein (CHIP), a ubiquitin ligase present in the 
cytoplasm, inhibits cancer stem-like cell activity in breast tumours and suppresses 
proliferation and metastasis of cancer cells [51]. Reduced CHIP expression has also been 
associated with high histological grade, hormonal receptor negativity and poor prognosis in 
breast cancer [52]. Aberrant ubiquitination may be responsible for enhanced cancer stem cell-
like functions and EMT of breast cancer cells underlying LVI and metastasis.   
KLHL7 positivity was recognised in the cytoplasm of invasive cancer cells. Although 
occasional cases showed nuclear staining the number was small for reliable statistical 
analysis and the expression was weak to moderate and seen simultaneously with cytoplasmic 
staining. High cytoplasmic staining of KLHL7 was associated with poor outcome in breast 
cancer patients. Importantly, the association with poor outcome was independent of other 
prognostic variables. Although no association between KLHL7 CNA and outcome was 
identified in the METABRIC cohort, the number of cases with CNA was limited with less 
than 2% showing copy number loss. Using the large cohort of Breast Cancer Gene-
Expression Miner, the association between KLHL7 mRNA expression and outcome was 
highly significant.   
 
CONCLUSIONS 
KLHL7 expression was related with molecular subtypes of breast cancer at genomic, 
transcriptomic and proteomic levels, and was strongly correlated with poorly differentiated 
tumours with LVI and with expression p53 and PIK3CA. KLHL7 may be released into the 
cytoplasm and ubiquitinates proteins involved in oncogenic pathways with the other factors 
involved in PI3K pathway. This may explain at least in part why the cytoplasmic expression 
of KLHL7 is an indicator of aggressive features and poor outcome in breast cancer.  
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Figure legends 
Figure 1. Immunohistochemical staining of KLHL7 to assay protein expression in breast 
cancer tissue showing (a) no staining, (b) weak staining, (c) moderate staining and (d) strong 
staining in the cytoplasm of cancer cells. 
 
Figure 2. Cumulative survival of breast cancer patients stratified by KLHL7 expression in 
breast tumours. (a) Significant differences were noted in survival of patients with high and 
low KLHL7 mRNA expressions using Breast Cancer Gene Expression Miner v4.0 [19] (p < 
0.0001). (b) Ten-year breast cancer specific survival was significantly worse in the KLHL7 
protein expression-positive group than in the expression-negative group (p = 0.0011). 
 
Figure 3. Morphological characteristics of KLHL7 immunohistochemistry in breast cancer 
tissue. (a) The immunohistochemical expression of KLHL7 was different between invasive 
carcinoma, intraductal cancer cells, and normal mammary gland adjacent to the tumour 
(Black arrow: invasive carcinoma, Grey arrow: intraductal cancer cells and white arrow: 
normal mammary gland). (b) Normal mammary gland cells showed absent or weak KLHL7 
staining. The reactivity of normal myoepithelial cells around epithelium (Black arrow) tended 
to be higher than those of normal epithelium. (c) Invasive cancer cells showed strong KLHL7 
staining. The reactivity was mainly recognized in the cytoplasm. (d) The degree of KLHL7 
immunohistochemical expression in invasive cancer cells was stronger than those of 
intraductal cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Association of KLHL7 copy number and KLHL7 mRNA expression with clinicopathological characteristics 
Characteristic 
Expression of KLHL7 (Copy number) 
p Characteristics 
Expression of KLHL7 (mRNA) 
p 
Loss  Neutral  Gain Total >Median <Median Total 
Tumour size 
> 2 cm 
16 
(1.2%) 
1208 
(90.4%) 
113 
(8.5%) 
1337 
0.13 Tumour size 
> 2 cm 
670 
(50.0%) 
668 
(50.0%) 
1338 
0.72 
< 2 cm 
7 
(1.1%) 
573 
(93.0%) 
36 
(5.8%) 
616 < 2 cm 
303 
(49.3%) 
313 
(50.7%) 
616 
Nodal status 
Positive 
8 
(0.9%) 
846 
(90.3%) 
83 
(8.9%) 
937 
0.069 Nodal status 
Positive 
462 
(49.3%) 
476 
(50.7%) 
938 
0.51 
Negative 
15 
(1.4%) 
953 
(92.1%) 
67 
(6.5%) 
1035 Negative 
525 
(50.7%) 
510 
(49.3%) 
1035 
Histological 
grade 
Grade 3 
14 
(1.5%) 
865 
(90.9%) 
73 
(7.7%) 
952 
0.45 
Histological 
grade 
Grade 3 
445 
(46.8%) 
507 
(53.3%) 
952 
0.010* 
Grade 1, 2 
8 
(0.9%) 
860 
(91.6%) 
71 
(7.6%) 
939 Grade 1, 2 
495 
(52.7%) 
445 
(47.3%) 
940 
Molecular 
subtype 
Luminal A 
5 
(0.7%) 
665 
(92.6%) 
48 
(6.7%) 
718 
<0.0001* 
Molecular 
subtype 
Luminal A 
396 
(55.2%) 
322 
(44.8%) 
718 
<0.0001* 
Luminal B 
8 
(1.6%) 
446 
(91.4%) 
34 
(7.0%) 
488 Luminal B 
223 
(45.7%) 
265 
(54.3%) 
488 
HER2-
enriched 
0 
(0.0%) 
205 
(85.4%) 
35 
(14.6%) 
240 
HER2-
enriched 
133 
(55.4%) 
107 
(44.6%) 
240 
Basal-like 
10 
(3.0%) 
296 
(90.0%) 
23 
(7.0%) 
329 Basal-like 
130 
(39.5%) 
199 
(60.5%) 
329 
Normal-like 
0 
(0.0%) 
189 
(95.5%) 
9 
(4.5%) 
198 Normal-like 
104 
(52.3%) 
95 
(47.7%) 
199 
Some variables do not add up to 1980 for all patients due to missing data.                                                                                                                                                                                                                                                                                                                                    
* Significant difference p<0.05. 
  
Table 2. Correlation between KLHL7 expression and clinicopathological characteristics 
Characteristic 
Expression of KLHL7 
p 
Low High Total 
ER 
Positive 306 (46.9%) 346 (53.1%) 652 
0.015* 
Negative 101 (38.1%) 164 (61.8%) 265 
PgR 
Positive 244 (47.2%) 273 (52.8%) 517 
0.051 
Negative 163(40.8%) 237 (59.3%) 400 
HER2 
Positive 48(37.2%) 81 (62.8%) 129 
0.077 
Negative 359 (45.6%) 429 (54.4%) 788 
Tumour size 
> 2cm 219 (42.4%) 297 (57.6%) 516 
0.18 
< 2cm 188 (46.9%) 213 (53.1%) 401 
Nodal status 
Positive 160 (42.3%) 218 (57.7%) 378 
0.29 
Negative 247 (45.8%) 292 (54.2%) 539 
Histological grade 
Grade 3 193 (38.7%) 306 (61.3%) 499 
0.00015* 
Grades 1, 2 214 (51.2%) 204 (48.8%) 418 
Lymphovascular invasion 
Positive 157 (40.3%) 233 (59.7%) 390 
0.030* 
Negative 250 (47.4%) 277 (52.6%) 527 
Intrinsic Subtype 
Luminal A-like 117 (52.2%) 107 (47.8%) 224 
0.026* 
Luminal B-like 166 (45.1%) 202 (54.9%) 368 
HER2 (non Luminal)  24(35.3%) 44 (64.7%) 68 
Luminal-HER2 24 (39.3%) 37 (60.7%) 61 
Triple negative 76(38.8%) 120 (61.2%) 196 
PIK3CA 
Low 81 (52.3%) 74 (47.7%) 155 
0.044* Moderate 87 (47.8%) 95 (52.2%) 182 
High 156 (41.1%) 224 (58.9%) 380 
pAKT 
Low 65 (43.3%) 85 (56.7%) 150 
0.82 
High 206 (42.3%) 281 (57.7%) 487 
p53 
Low 294 (47.5%) 325 (52.5%) 619 
0.0015* 
High 102 (36.2%) 180 (63.8%) 282 
The variables of PIK3CA, pAKT and p53 do not add up to 917 for all patients due to missing data.                                                                                                                                                                                                                                                                                                                                    
* Significant difference p<0.05. 
 
 
  
Table 3. Survival analysis based on clinicopathological characteristics, including KLHL7 expression 
Characteristics 
Univariate analysis  Multivariate analysis  
Hazard Ratio 95% CI p Hazard Ratio 95% CI p 
KLHL7 
Low Reference Reference 
High 1.53 1.18–1.99 0.0011* 1.32 1.02–1.71 0.037* 
ER 
Positive Reference Reference 
Negative 1.97 1.53–2.54 <0.0001*  0.83 0.59–1.18 0.30 
PR 
Positive Reference Reference 
Negative 2.33 1.81–3.01 <0.0001*  1.80 1.27–2.53 0.00085* 
HER2 
Negative Reference Reference 
Positive 2.27 1.69–3.04 <0.0001*  1.44 1.06–1.96 0.019* 
Tumour size 
< 2cm Reference Reference 
> 2cm 2.34 1.77–3.08 <0.0001*  1.62 1.22–2.16 0.00085* 
Nodal status 
Negative Reference Reference 
Positive 2.59 2.01–3.34 <0.0001* 2.31 1.79–3.00 <0.0001* 
Histological grade 
Grade 1-2 Reference Reference 
Grade 3 3.37 2.51–4.52 <0.0001* 2.28 1.64–3.15 <0.0001* 
* Significant difference p<0.05. 
 
 
 
Supplementary File 1. Characteristics of the Nottingham primary cohort patients 
 
Age range (years) Patients (n) 
24–40 104 
41–59 535 
60 and over 278 
Menopausal status 
Pre 393 
Post 524 
Tumour size 
< 2.0cm 401 
> 2.0 cm 516 
Nodal status 
Negative 539 
Positive 378 
Lymphovascular invasion 
Negative 527 
Positive 390 
Type of breast surgery 
Breast-conserving surgery 372 
Mastectomy 545 
Axillary surgery 
Sampling alone 500 
Axillary lymph node dissection 351 
No surgery 5 
Unknown 61 
Chemotherapy 
Yes 199 
No 671 
Unknown 47 
Endocrine therapy 
Yes 337 
No 533 
Unknown 47 
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